Related Stories
Progress
For Sopharma AD this effort is another contribution to an excellent corporate governance file.
Letter to the shareholders
2020 questioned all boundaries, challenged us to make difficult choices, to sacrifice our own comfort to protect the most vulnerable. It's been a difficult year, both personally and professionally, but let us remember it with the things we've achieved nonetheless.
As a team we put in a lot of effort, were flexible and were able to maintain a normal rhythm of work, provide a safe environment for our employees and partners and remain stable in extremely uncertain times. We remained a key pillar of the peer network supporting the government in addressing the challenges in the healthcare system faced and we helped whenever needed.
We have launched several successful campaigns, expanded the families of our most successful products, offered new forms more convenient for application for patients at different ages. Against the backdrop of the COVID-19 pandemic, we also had to overcome some administrative obstacles in significant markets, such as the serialization in Russia, and by the end of the year we had completed all major activities in this direction. We achieved remarkable growth in some of the major markets in the top ten, mostly as a result of successful changes in out local trade policy. We started many interesting partnerships in various fields - production, trade, marketing, services, making building long-term, successful and mutually beneficial relationships a top priority.
The most important thing for any crisis is what state we will be in when we get out of it. We believe that everything we have done together has made us even more resilient, inventive and flexible. Let's wish ourselves a healthier and calmer year. Thank you for your trust.
Ognian Donev, PhD
Chairman of the Board of Directors and Executive Director of "Sopharma" AD
Key Financial Results
| Indicators | 31.12.2020 BGN '000 | 31.12.2019 BGN '000 | change% |
|---|---|---|---|
| Sales revenues | 1,438,826 | 1,281,587 | 12.3% |
| Deprecation and amortization (EBITDA) | 92,433 | 103,696 | -10.9% |
| Operating profit | 45,800 | 59,692 | -23.3% |
| Net profit | 25,280 | 84,359 | -70% |
| Indicators | 31.12.2020 BGN '000 | 31.12.2019 BGN '000 | CHANGE % |
|---|---|---|---|
| Non-current asset | 629,935 | 626,172 | 0.6% |
| Current asset | 612,177 | 549,100 | 11.5% |
| Equity | 566,595 | 575,772 | -1.6% |
| Non-current liabilities | 131,066 | 115,448 | 13.5% |
| Current liabilities | 544,451 | 484,052 | 12.3% |
| Ratios | 31.12.2020 | 31.12.2019 |
|---|---|---|
| EBITDA/sales revenue | 6.4% | 8.1% |
| Operating profit/Sales revenue | 3.2% | 4.7% |
| Net profit/Sales revenue | 1.8% | 6.6% |
| Borrowed capital/Equity | 1.19 | 1.04 |
| Net debt/EBITDA, annualized | 4.3х | 4.68x |
Significant Events
14 April
The company “Pharmachim” EOOD, Serbia, was established. Sopharma AD is the sole owner of the company's capital.
5 June
The Annual General Meeting of “Sopharma” AD was held, at which a decision to pay a gross dividend for 2019 in the amount of BGN 0.07 per sharewas made.
4 August
A merger of “Sopharma Trading Pharmaceuticals” D.o.o. in “Sopharma Trading” D.o.o. was registered, by merging the assets and liabilities of the two companies.
25 September
The Extraordinary General Meeting of Shareholders of "Sopharma" AD was held at which a decision to pay a 6-month gross dividend for 2020 in the amount of BGN 0.04 per sharewas made.
1 October
“Sopharma Trading” AD finalized the acquisition of sole control over the companies “SCS Franchise” AD and “Sanita Franchising” AD.
29 December
“Sopharma” AD sold its shares in the capital of “Aromania” AD.
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
New Development and Products
 |
New Products |
Marketing Authorization was obtained for 5 new medicinal products - Solifenax 5 mg film-coated tablet (Bulgaria), Ambrolitin 30 mg/5 ml syrop (Bulgaria, Latvia, Estonia), Ketoprofen 100 mg/ 2 ml solution for injection (Bulgaria), Sofazolon 40mg powder and solvent for solution for injection (Bulgaria), Dexketoprofen 50mg/2ml solution for injection (Latvia, Lithuania, Estonia). |
 |
Expected in 2021 Three to five new products are expected to be introduced by the end of the 2021. |
 |
 |
Developments 30 production processes and technologies are in transfer, validation and optimization. Pharmaceutical development is underway for 18 new products for the company. |
30 PRODUCTION PROCESSES 18 NEW PRODUCTS |
